open access

Vol 11, No 1 (2010): Practical Diabetology
Research paper
Published online: 2010-04-21
Get Citation

Cost-utility analysis for insulin aspart and biphasic insulin aspart in treatment of type 1 and 2 diabetes mellitus

Daria Szmurło, Marcin Hetna, Przemysław Ryś, Iwona Skrzekowska-Baran
Diabetologia Praktyczna 2010;11(1):24-34.

open access

Vol 11, No 1 (2010): Practical Diabetology
Original articles (submitted)
Published online: 2010-04-21

Abstract

INTRODUCTION. In this analysis costs and utilities of treatment with rapid-acting and biphasic insulin analogues (aspart) were compared with those of human insulin in patients with type 1 and 2 diabetes mellitus.
MATERIAL AND METHODS. This cost-utility analysis was based on the CORE Diabetes Model, adapted to Polish circumstances. Two comparisons were performed: insulin aspart vs. human insulin in a multiple injection regimen in type 1 diabetes mellitus and biphasic insulin aspart vs. human insulin mixture in type 2 diabetes mellitus. The enhanced payer’s perspective was adopted, i.e. total costs incurred by the public payer and the patient were taken into account. Health effects were expressed in quality-adjusted life years (QALY).
RESULTS. Type 1 diabetes mellitus. The mean number of QALY gained was 5.39 in the aspart group and 4.85 in the human insulin group. Costs of treatment per patient were 53,454 PLN for treatment with insulin aspart and 50,048 PLN for treatment with human insulin. The cost for an additional QALY gained was 6,351 PLN. Type 2 diabetes mellitus. The mean number of QALY was 5.06 for biphasic insulin aspart and 4.95 for human insulin mixture. Costs of treatment per patient were 30,079 PLN for treatment with biphasic insulin aspart and those generated by human insulin mixture were 24,970 PLN. The cost for an additional QALY gained was 49,425 PLN.
CONCLUSIONS. Both rapid-acting and biphasic insulin aspart improve quality of life of patients with type 1 and 2 diabetes mellitus in comparison with human insulin. In Polish circumstances they are cost-effective treatment options. This was confirmed by a high cost-utility ratio, which in both cases was lower than the cost-utility threshold assumed in Poland.
(Diabet. Prakt. 2010; 11, 1: 24-34)

Abstract

INTRODUCTION. In this analysis costs and utilities of treatment with rapid-acting and biphasic insulin analogues (aspart) were compared with those of human insulin in patients with type 1 and 2 diabetes mellitus.
MATERIAL AND METHODS. This cost-utility analysis was based on the CORE Diabetes Model, adapted to Polish circumstances. Two comparisons were performed: insulin aspart vs. human insulin in a multiple injection regimen in type 1 diabetes mellitus and biphasic insulin aspart vs. human insulin mixture in type 2 diabetes mellitus. The enhanced payer’s perspective was adopted, i.e. total costs incurred by the public payer and the patient were taken into account. Health effects were expressed in quality-adjusted life years (QALY).
RESULTS. Type 1 diabetes mellitus. The mean number of QALY gained was 5.39 in the aspart group and 4.85 in the human insulin group. Costs of treatment per patient were 53,454 PLN for treatment with insulin aspart and 50,048 PLN for treatment with human insulin. The cost for an additional QALY gained was 6,351 PLN. Type 2 diabetes mellitus. The mean number of QALY was 5.06 for biphasic insulin aspart and 4.95 for human insulin mixture. Costs of treatment per patient were 30,079 PLN for treatment with biphasic insulin aspart and those generated by human insulin mixture were 24,970 PLN. The cost for an additional QALY gained was 49,425 PLN.
CONCLUSIONS. Both rapid-acting and biphasic insulin aspart improve quality of life of patients with type 1 and 2 diabetes mellitus in comparison with human insulin. In Polish circumstances they are cost-effective treatment options. This was confirmed by a high cost-utility ratio, which in both cases was lower than the cost-utility threshold assumed in Poland.
(Diabet. Prakt. 2010; 11, 1: 24-34)
Get Citation

Keywords

diabetes; aspart; QALY; cost

About this article
Title

Cost-utility analysis for insulin aspart and biphasic insulin aspart in treatment of type 1 and 2 diabetes mellitus

Journal

Clinical Diabetology

Issue

Vol 11, No 1 (2010): Practical Diabetology

Article type

Research paper

Pages

24-34

Published online

2010-04-21

Bibliographic record

Diabetologia Praktyczna 2010;11(1):24-34.

Keywords

diabetes
aspart
QALY
cost

Authors

Daria Szmurło
Marcin Hetna
Przemysław Ryś
Iwona Skrzekowska-Baran

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl